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Abstract
Infantile spasms is an epileptic encephalopathy of early infancy with specific clinical and electroencephalographic (EEG) features,
limited treatment options, and a poor prognosis. Efforts to develop improved treatment options have been hindered by the lack of
experimental models in which to test prospective therapies. The neuropeptide adrenocorticotropic hormone (ACTH) is effective
in many cases of infantile spasms, although its mechanism(s) of action is unknown. This review describes the emerging candidate
mechanisms that can underlie the therapeutic effects of ACTH in infantile spasms. These mechanisms can ultimately help to
improve understanding and treatment of the disease. An overview of current treatments of infantile spasms, novel conceptual
and experimental approaches to infantile spasms treatment, and a perspective on remaining clinical challenges and current
research questions are presented here. This summary derives from a meeting of specialists in infantile spasms clinical care and
research held in New York City on June 14, 2010.
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Infantile spasms or West syndrome is an epileptic encephalopa-
thy of infancy with a number of unique features that position it
among the most severe epilepsies of childhood. Many aspects of
the diagnosis and treatment of infantile spasms are well
described and familiar to child neurologists. The clinical presen-
tation includes intermittent spasm-like seizures involving flex-
ion or extension, or mixed flexion-extension movements of
the arms, legs, or trunk. These seizures typically occur in clus-
ters, often during sleep-wake transitions. The onset of infantile
spasms usually occurs in the middle of the first year of life, often
accompanied by stagnation or decline of developmental mile-
stones. The appearance of infantile spasms weeks to months
following a precipitating brain insult (‘‘latent period’’) implies
that a period of epileptogenesis is occurring,1 possibly with
features unique to this syndrome. The existence of a latent
period also raises the possibility of preventive intervention.
Infantile spasms has numerous etiologies (more than 200
already documented) but can also occur in previously healthy,
normally developing children.2,3 Symptomatic etiologies
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include genetic and acquired causes such as hypoxic ischemic
encephalopathy, tuberous sclerosis complex, brain malforma-
tions, and central nervous system infections. Of note, these
symptomatic etiologies overlap with those responsible for
Lennox-Gastaut syndrome, which usually appears after 2 years
of age, suggesting that the form of epileptic encephalopathy in
a given child depends upon the stage of brain development at
which the neurologic insult occurs. Alternatively, an epileptic
encephalopathy such as infantile spasms can present at an ear-
lier age, then later evolve into Lennox-Gastaut syndrome as the
brain develops.4
Novel genetic etiologies of infantile spasms are being dis-
covered rapidly, with an almost bewildering array of mutations
affecting synapse development, gene transcription, protein
phosphorylation, ion transport, and numerous other cellular
functions now described.5-7 While each of these genetic muta-
tions is rare, collectively they comprise an increasing propor-
tion of infantile spasms etiologies.8 The fraction of infantile
spasms cases with a cryptogenic or uncertain etiology is stea-
dily decreasing over time as modern genetic testing, imaging,
and biochemical diagnostic techniques improve. Based on this
burgeoning information, a new nosology has been proposed for
infantile spasms, with the categories of genetic, structural/
metabolic, and unknown replacing the former terms crypto-
genic, symptomatic, and idiopathic, respectively.9 (In this
review, we use the former terms because they were used in the
clinical studies that are discussed.) The clinical aspects of
infantile spasms and its treatment have been reviewed in detail
in a recent consensus report.3
The goals of infantile spasms treatment are to stop the
spasms, normalize the abnormal interictal EEG pattern (hyp-
sarrhythmia) that underlies the encephalopathy, and optimize
neurodevelopmental outcome. Treatment of infantile spasms
involves a unique set of therapies (discussed in further detail
below). The 39–amino acid adrenocorticotropic hormone
(Highly Purified Acthar1 Gel, hereafter referred to as ACTH)
is the most commonly used treatment for infantile spasms, yet
the exact mechanisms of its anticonvulsant (and possibly anti-
epileptogenic) actions are unknown. ACTH therapy can be
associated with significant adverse effects and high cost, and
some cases of infantile spasms do not respond to ACTH.
Furthermore, emerging research suggests that some etiologies
of infantile spasms respond best to other specific therapies.10,11
For example, vigabatrin, a g-aminobutyric acid (GABA) trans-
aminase inhibitor, is considered the first line of treatment
for infantile spasms in children with tuberous sclerosis
complex.12,13 In fact, it has been proposed that prophylactic
antiepileptic treatment prior to the onset of infantile spasms
might yield improved outcome in children with tuberous
sclerosis complex, although confirmative data have not yet
been reported.14,15 Several other treatments, discussed below,
have had variable success. The prognosis of infantile spasms
is generally poor, especially in symptomatic cases. For all of
these reasons, optimization of treatment choice and timing of
administration of infantile spasms treatment is of utmost
urgency (Figure 1).
Advances in understanding the underlying mechanisms,
pathophysiology, and treatment effectiveness of infantile
spasms have been limited by the lack of valid animal models
in which to test new hypotheses and develop new treatments.
However, the recent emergence of clinically relevant animal
models of infantile spasms, potential new approaches to treat-
ment such as melanocortin receptor activation, and the continu-
ing gap between the recognition of infantile spasms and its
effective treatment, led to a summit meeting of experts in
pediatric epilepsy and basic science to address how these new
data might impact therapy. Although numerous unanswered
questions remain about the underlying pathophysiology and
treatment effectiveness, meeting participants concluded that a
summary of the topics discussed would be informative to phy-
sicians treating patients with infantile spasms.
ACTH and Other Treatments of
Infantile Spasms
Among the unique aspects of infantile spasms is the profile of
pharmacologic responsiveness. Typically, infantile spasms
respond to conventional antiepileptic drugs inconsistently, if
Figure 1. Schematic timeline showing precipitating neurologic insult followed by a period of epileptogenesis (latent period), which in turn is
followed by onset of infantile spasms (West syndrome) and hypsarrhythmia. Although West syndrome is usually treated after the onset of
spasms, it might be possible to avert some of the long-term sequelae (persistent seizures, cognitive impairment) by intervening during the latent
period in cases in which the development of spasms is likely.
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at all. However, as initially described in 1958, infantile spasms
frequently responds dramatically to the neuropeptide ACTH.16
Since that original report, numerous studies have examined
various dosage regimens and protocols of ACTH administra-
tion, as well as comparisons of ACTH with steroids such as
prednisone and other agents. The most recent comprehensive
review of data regarding ACTH effectiveness is found in a
practice parameter published in 2004 by the American Acad-
emy of Neurology and Child Neurology Society.17 In that
report, an effective treatment response in infantile spasms was
defined as complete cessation of spasms plus abolition of the
hypsarrhythmia. The requirement of all-or-none responsive-
ness differs from the usual definition of treatment effectiveness
accepted for other forms of epilepsy. The all-or-none require-
ment reflects a consensus that unless hypsarrhythmia resolves,
cognitive recovery is likely to be incomplete and disease pro-
gression (eg, to Lennox-Gastaut syndrome or other forms of
epilepsy) is probable.
ACTH was deemed ‘‘probably effective’’ for the termina-
tion of infantile spasms and resolution of hypsarrhythmia.17
The practice parameter evaluated 14 ACTH treatment studies,
5 of which were randomized controlled trials (3 involving
Highly Purified Acthar Gel). The parameter concluded that
intramuscular injection of high-dose ACTH (150 IU/m2 body
surface area/d, divided into 2 daily doses) was more effective
in the treatment of infantile spasms than oral prednisone at
a dose of 2 mg/kg/d divided into 2 doses over 2 weeks of
treatment.18 The practice parameter could not determine a dose
response curve for ACTH by comparing low- versus high-dose
treatments,19 because of methodological variability, including
the rate of dose escalation of low-dose treatment, as well as the
finding that the response to low-dose ACTH 20 IU/day did not
differ from prednisone at 2 mg/kg/d.20 It was concluded that
these studies were generally underpowered to detect clinically
relevant treatment differences. Therefore, according to the
practice parameter, there is insufficient evidence that oral
corticosteroids such as prednisone are effective in the treatment
of infantile spasms, with a maximum response rate of about
30%, which was not different from placebo.17
The recent United Kingdom Infantile Spasms Study com-
pared treatment with vigabatrin versus the synthetic, truncated
ACTH analog (ACTH 1-24; tetracosactide, intramuscular
depot form) or prednisolone.21 Patients with tuberous sclerosis
complex were not included in the United Kingdom Infantile
Spasms Study. The study used very low dose ACTH 1-24 (40
IU every other day—because of its long duration of action,
on the order of 24-36 hours) and a very high dose of predniso-
lone (40 mg/d; duration of action, 18-36 hours). The primary
endpoint was the clinical cessation of spasms by parental
report, without requiring the abolition of hypsarrhythmia or
confirmation of spasms cessation by EEG. Therefore, these
data cannot be compared directly to the randomized clinical
trials that used the combined endpoint of no spasms and no
hypsarrhythmia confirmed by prolonged video EEG that
formed the basis for the American Academy of Neurology/
Child Neurology Society practice parameter. In addition, even
with its endpoint, the United Kingdom Infantile Spasms Study
was underpowered to compare treatment effects of ACTH 1-24
versus prednisolone. No study to date has directly compared
synthetic, truncated ACTH analogs with the natural, full-
sequence form of ACTH. Also, no study has compared high-
dose ACTH with high-dose corticosteroids. Thus, equivalence
in dose, adrenal effects, central nervous effects, and biological
activity cannot be presumed. It can be concluded that low-dose
ACTH is sufficient for release of natural corticosteroids from
adrenal glands, whereas high-dose ACTH is needed for a direct
action on the central nervous system. In that regard, penetration
of ACTH across the blood-brain barrier appears to be limited,
so the central nervous system effects of this neuropeptide
require a fuller explanation, as discussed below.22
According to the cited literature, high-dose ACTH has
superior efficacy compared with low-dose corticosteroids for
the treatment of infantile spasms and hypsarrhythmia (87%
vs 27% response rate, respectively).18 Similarly, ACTH is the
only drug treatment for which long-term infantile spasms out-
comes are available. Patients treated early (within 1 month of
spasms onset or before the onset of developmental decline)
with ACTH 1-24 show lower rates of relapse, better intellectual
development and lower incidence of later epilepsy.23-25 This
beneficial effect is particularly applicable to cryptogenic infan-
tile spasms; efficacy in many cases of symptomatic infantile
spasms is incomplete or recurrence occurs after an initial favor-
able response. In Finnish studies, there was no difference in
response rate or relapse rate comparing low-dose (20-40 IU/
day) and high-dose (120 IU/day) ACTH 1-24, and better
long-term cognitive outcomes were reported with the low-
dose regimen.26-28
Based on the above reports, ACTH, especially the high-dose
regimen, continues to be the clinical standard of treatment of
infantile spasms in the United States and several other coun-
tries.3,29,30 The treatment effect of ACTH has a rapid onset,
with a mean time to treatment response of 2 days. The all-or-
none resolution of both spasms and hypsarrhythmia suggests
a disease-modifying effect of high-dose ACTH, a notion sup-
ported by clinical observations that in many instances, once
spasms have ceased and ACTH is withdrawn, epileptic seizures
may not recur. Approximately 40% to 60% of patients treated
with ACTH 1-24 have long-term seizure freedom.11,31 Treat-
ments with high-dose ACTH indicate initial efficacy rates of
87% and relapse rates between 14% and 20%.18 Treatment
with ACTH or ACTH 1-24 should be as short as possible
(approximately 2 weeks followed by a taper) to avoid adverse
effects.3,18,32,33 Prolonged EEG monitoring including sleep is
necessary to confirm the cessation of hypsarrhythmia.
Despite the documented effectiveness of ACTH in the treat-
ment of infantile spasms, its molecular and pathophysiological
effects are not entirely known. Particularly intriguing are the
observations that there is typically a lag time of approximately
48 hours before the onset of an ACTH effect, and that the clin-
ical effect is typically all-or-none with complete cessation of
the spasms and normalization of the EEG. This clinical action
profile, with is very atypical for a ‘‘simple anticonvulsant’’
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effect, might provide clues to the mechanism by which ACTH
suppresses infantile spasms. One possibility, discussed further
below, is that ACTH might suppress infantile spasms via
actions on melanocortin receptors.
Notably, the side-effect profile of high-dose ACTH and
ACTH 1-24 (including hypertension, immune suppression,
fluid retention, and central nervous system effects such as irrit-
ability), while usually reversible and not affecting every
patient, can be significant. The recurrence of spasms in treated
patients further supports the need for a search for alternative
therapies.
Finally, it is uncertain how systemic ACTH exerts effects
within the brain since the blood-brain barrier is relatively
impermeable to ACTH.34 Spinal fluid ACTH derives largely
from ACTH released by pro-opiomelanocortin-positive neu-
rons of the arcuate nucleus of the hypothalamus and pro-
opiomelanocortin-positive neurons of the nucleus tractus
solitarius of the medulla. Cerebrospinal fluid ACTH levels
are low in untreated infantile spasms,35-38 suggesting deficient
synthesis within the brain of ACTH and the related endo-
genous peptide, a-melanocyte-stimulating hormone. Cere-
brospinal fluid ACTH levels do not rise, and can even fall,
with ACTH treatment, suggesting feedback inhibition of
ACTH release.39-41 How ACTH achieves access to the brain
or whether ACTH synthesis within the brain increases (or both)
is uncertain. Both the arcuate nucleus and the nucleus tractus
solitarius abut circumventricular areas where the blood-brain
barrier is permeable, providing a potential site of access for
systemically administered ACTH to the brain and to pro-
opiomelanocortin-positive neurons. Steroid-independent mela-
nocortin receptors are found in both nuclei.
There is no postdose spike in the cerebrospinal fluid con-
centration of ACTH after a systemic injection. However, as a
physiological ‘‘sink,’’ cerebrospinal fluid and the cerebrospinal
fluid–blood barrier may not be the optimal compartment to
study whether ACTH has direct central actions. Effects of
ACTH (the parent compound or active fragments) on neurons
and glia, especially considering the low concentrations needed
for receptor activation, are not necessarily reflected in cere-
brospinal fluid levels. An alternative hypothesis is that ACTH
acts in infantile spasms, at least in part, by stimulating the pro-
duction of neurosteroids in the periphery, which are able to
enter the brain and exert an anticonvulsant action.22
In addition to the well-recognized ability of ACTH to
stimulate the synthesis of glucocorticoids in the zona
fasciculata of the adrenal cortex, ACTH also enhances the
synthesis of the mineralocorticoid precursor deoxycorticoster-
one in the same region of the adrenal gland. Deoxycorticoster-
one is not only a precursor for aldosterone but it can be
converted to the neurosteroid allotetrahydrodeoxycorticoster-
one, which is a powerful positive modulator of GABAA
receptors and a potent anticonvulsant.42 Despite their steroid
structures, allotetrahydrodeoxycorticosterone and related
GABAA receptor–modulating neurosteroids differ from tradi-
tional steroids in that they do not act through nuclear hormone
receptors to regulate gene expression. Whereas there is a
question about the blood-brain barrier permeability of ACTH,
allotetrahydrodeoxycorticosterone readily enters the brain.
Therefore, allotetrahydrodeoxycorticosterone might mediate
the therapeutic activity of ACTH in infantile spasms. Although
the neurosteroid hypothesis is attractive, mixed results with
other positive GABAA receptor modulators such as nitrazepam
(which can reduce spasm frequency but not eliminate hypsar-
rhythmia) and the synthetic neurosteroid analog ganaxolone
(discussed below) suggest that GABA receptor modulation
cannot fully explain the positive therapeutic effects of ACTH.
The possible role of neurosteroids in the action of ACTH
encouraged study of the synthetic neurosteroid analog ganaxo-
lone in infants with infantile spasms.43,44 In an open-label, add-
on, nonblinded clinical study of children with infantile spasms
refractory to other agents (including ACTH or vigabatrin),
ganaxolone was well tolerated but showed only modest and
nonsignificant effectiveness (spasm frequency reduced 50%
in about one-third of cases); its effect on hypsarrhythmia, a
requirement for antiepileptic effectiveness in infantile spasms,
is unknown.45 A recent multicenter randomized, placebo-
controlled clinical trial showed no clear statistically significant
treatment effect although some subjects did appear to demon-
strate a treatment-related reduction in spasm clusters as
assessed by 24-hour video EEG recordings.46
Other treatments have been successful in certain etiological
subtypes of infantile spasms.10 For example, children with
tuberous sclerosis complex respond well to vigabatrin.13,47 The
American Academy of Neurology/Child Neurology Society
practice parameter concluded that vigabatrin is ‘‘possibly
effective’’ in infantile spasms.17 Modest dose-dependent bene-
fit from vigabatrin has been shown in a recent randomized trial
of 221 children with infantile spasms.48 The potential for visual
field loss following vigabatrin treatment is widely reported and
this side effect must be weighed against potential benefit in
children with infantile spasms.49 Recent data suggest that the
risk of visual field loss in infants treated with vigabatrin for
infantile spasms may not be as high as in older individuals
receiving this drug.50,51
A variety of alternative treatments for infantile spasms has
been utilized, including zonisamide, topiramate, valproate, and
the ketogenic diet; these agents have not been validated in
large-scale studies, but remain options when first-line agents
such as ACTH and vigabatrin fail.3 There is no convincing
objective evidence for the efficacy of these alternative thera-
pies at this time.17 Surgery can play a role in selected patients
with infantile spasms secondary to cortical dysplasia.52
In conclusion, clinicians choose a therapy for infantile
spasms based on published evidence as well as personal expe-
rience, cost, and side-effect profile.29,53,54 Therapeutic choice
also varies by geography—pyridoxine is a first-line treatment
in Japan55,56 while physicians in many European countries and
Canada begin with vigabatrin, irrespective of the etiology of
the infantile spasms.57 It is clear that no current therapy for
infantile spasms is ideal and that novel agents are needed. As
described in the next section, melanocortin receptor agonists,
which share structural features with ACTH, might comprise
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one such alternative. This approach is further supported by
recent data attributing ACTH responsiveness to genetic poly-
morphisms in melanocortin receptor genes.58
Melanocortin Receptors
ACTH and a-, b-, and g-melanocyte-stimulating hormone
comprise a family of endogenous peptides called melanocortins,
derived from a common precursor, pro-opiomelanocortin. Mela-
nocortins are critical for a variety of physiological processes,
including anti-inflammation, neuroprotection, and blood pressure
regulation. The cloning and characterization of 5 subtypes of
melanocortin receptors, each with a different distribution and
function within the body and brain, has led to increased under-
standing of the role of these peptides and their binding in phy-
siological and pathophysiological processes.59 Melanocortin
receptors consist of 7 transmembrane G-protein-coupled recep-
tors that signal via the activation of adenylyl cyclase and increase
of cyclic adenosine monophosphate. Table 1 lists some of the
properties of the 5 types of melanocortin receptors. Commercially
available melanocortin receptor antibody assays have not been
fully validated, so there is some uncertainty regarding the exact
distribution of melanocortin receptors. The best evidence sug-
gests that melanocortin receptor subtypes 3 and 4 are primarily
neuronal though all melanocortin receptor subtypes have been
found in the brains of various species.60 Melanocortin receptor
type 4 is distributed more widely in the brain, including cortex,
thalamus, and brainstem, whereas melanocortin receptor type 3
has a more restricted localization, including such seizure-
sensitive brain cortical regions as the limbic system. ACTH has
been shown to act on melanocortin receptor type 4 in the amyg-
dala to suppress endogenous convulsant molecules.61 ACTH is
capable of activating all 5 melanocortin receptors, while only
ACTH recognizes melanocortin receptor type 2.
Melanocortin receptor type 2 is primarily localized in the adrenal
cortex, where it promotes steroidogenesis.
Extra-adrenal influences of ACTH could play a role in sup-
pressing infantile spasms. As stated above, ACTH recognizes
all 5 melanocortin receptors (Figure 2). Therefore, the
peptide action is not limited to melanocortin receptor type
2-induced steroidogenesis but also includes effects mediated
by other melanocortin receptors. In this regard, one of the most
important properties of melanocortin receptors is that they
are anti-inflammatory. When a melanocortin binds to a mela-
nocortin receptor, the translocation of the nuclear transcription
factor NF-kB to the nucleus, a process mainly induced by
cytokines and other pro-inflammatory agents, is prevented.
Therefore, melanocortins inhibit the production of inflamma-
tory mediators, an effect that occurs in both peripheral tissues
and central and peripheral nervous systems. In addition, periph-
eral inflammatory responses are decreased by a central action
of melanocortins, via descending neural pathways.59,62 A vari-
ety of neurodegenerative processes that involve inflammation,
such as stroke, trauma, and epilepsy, could potentially be
exacerbated by NF-kB activation and lessened by NF-kB inhi-
bition (via melanocortins).63,64
The presence of melanocortin receptors in the brain and
their activation by endogenous and possibly exogenous ACTH
has led to a number of hypotheses regarding the action of these
compounds in infantile spasms.61 Much more work must be
done to understand the neuroprotective role of ACTH and per-
haps other melanocortins in infantile spasms. The availability
of validated test systems, some of which are described below,
offers an opportunity for translational research in the treatment
of infantile spasms—testing prospective compounds in animal
models and then moving promising candidate drugs from the
bench to the clinic.
Animal Models of Infantile Spasms
Using animal models, hypotheses about mechanisms can be
generated and tested and prospective treatment regimens for
infantile spasms can be evaluated. Historically, the lack of rel-
evant animal models has hampered the understanding of the
distinctive pathophysiology of infantile spasms. Similarly, the
search for a final common pathway among the diverse infantile
Table 1. Melanocortin Receptors
MCR Subtype Ligand Affinity Prevalent Tissue Expression Functions
MC1R a-MSH  ACTH >> g-MSH Melanocytes
Immune/inflammatory cells
Keratinocytes
Endothelial cells
Glial cells
Pigmentation
Antipyresis
Anti-inflammation
MC2R ACTH Adrenal cortex Steroidogenesis
MC3R g-MSH ¼ ACTH  a-MSH CNS
Macrophages
Autonomic functions
Anti-inflammation
MC4R a-MSH ¼ ACTH >> g-MSH CNS Energy homeostasis
Neuroprotection
MC5R a-MSH > ACTH > g-MSH Exocrine glands
Lymphocytes
Exocrine secretion
Immunoregulation
Abbreviations: MC, melanocortin; MCR, melanocortin receptor; MSH, melanocyte-stimulating hormone; ACTH, adrenocorticotropic hormone.
Courtesy of A. Catania, MD
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spasms etiologies has thus far failed to reveal a unifying
neurobiological mechanism.65,66 However, several investiga-
tors have recently developed animal models that mimic one
or more critical features of infantile spasms. These emerging
infantile spasms animal models have been reviewed in detail
recently6,67,68 and are summarized in Table 2. Criteria for an
ideal model of infantile spasms would include similar seizure
type, age of onset of seizures, spectrum of etiologies, EEG
features, developmental cognitive deficits, and a pharmacolo-
gical profile comparable with infantile spasms in humans.87
At a minimum, a putative animal model of infantile spasms
should exhibit postnatal seizures with an abnormal EEG plus
cognitive impairment. Obviously, no single rodent model will
replicate the human disorder exactly. Nevertheless, important
pathophysiological insights can be gained if appropriate ques-
tions are posed.
In parallel with the diverse etiologies of infantile spasms in
humans, a large variety of methods have been employed to
induce spasm-like seizures in animals, mimicking both genetic
causes (eg, Down syndrome with abnormal GABAB-receptor/
G-protein–coupled inward rectifying potassium channel subu-
nit 2 [GIRK2] function; mutations of the Aristaless-related
homeobox [ARX] gene causing GABAergic interneuron loss)
and symptomatic/acquired etiologies (eg, toxin injections to
create brain diffuse pathology; tetrodotoxin to abolish cortical
neuronal activity). Despite notable differences between mod-
els, it is worth emphasizing some of their common features.
Each model entails spasm-like seizures or other seizures early
in development in rodents that have been subject to a variety of
genetic mutations or exogenous agents as triggers. Some
seizures in these models resemble spasms; others have a semi-
ology more closely resembling limbic or complex partial
seizures (see Table 2). All models have EEG changes; some but
not all models demonstrate the typical interictal EEG abnormality
(hypsarrhythmia) and ictal EEG changes (electrodecrement)
seen in human infantile spasms—this variability is expected
considering the structural differences between brains of humans
and rodents, the latter having a lissencephalic cortex. In the
tetrodotoxin model, in which focal intracerebral infusion of the
sodium channel blocker tetrodotoxin ablates neuronal activity
and results in spontaneous seizures, electrographic recordings
of interictal and ictal activity are convincingly similar to human
examples.78
Seizures are seen at different postnatal ages across models,
with the specific genetic or neurologic insult interacting with
brain dysfunction at a particular developmental stage, resulting
in varied epilepsy phenotypes. In the multiple-hit model, sei-
zures occur at an age analogous to human infantile spasms,
while in the tetrodotoxin and ARX mutation models, they occur
somewhat later, but still within a specific age window. In some
models, seizures occur secondary to genetic mutations; in oth-
ers, seizures occur only in response to a provocative trigger, but
each model can be informative—seizures that are spontaneous
allow investigation of factors involved in epileptogenesis,
while seizures occurring only in response to an exogenous trig-
ger permit study of factors influencing network excitability.
Figure 2. Schematic illustration of melanocortin receptors (MCRs) types 2, 3, and 4, their activation by ACTH or other melanocortins,
and some of the possible physiological consequences of melanocortin receptor activation. It is conceivable that neuroprotection and/or
anti-inflammation can be obtained in infantile spasms with novel melanocortin receptor agonists.
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Both types of information will be useful in understanding the
complexity of infantile spasms generation. In addition, a mod-
el’s usefulness is enhanced if cognitive deficits can be demon-
strated; most models have fulfilled this criterion to some
degree. Deficits similar to those seen in children with infantile
spasms have been documented, such as learning and memory
impairments and autistic-like behaviors.
Regarding medication responsiveness, there is a paucity of
data in most models at this time. The ACTH 1-24 fragment
is effective in the Down syndrome model86 but ACTH is poorly
effective in the multiple-hit model and modestly effective in
increasing latency to onset of spasms in the betamethasone/
N-methyl-D-aspartate model. In the corticotropin-releasing hor-
mone model, in which limbic seizures are induced by small
doses of corticotropin-releasing hormone in the immature
brain,69 ACTH would not be expected to reduce seizures since
this peptide is downstream from the probable site of convulsant
action.88 Other agents have produced varied results. Vigabatrin
Table 2. Animal Models of Infantile Spasms
Model How Model Is Created Clinical Relevance Limitations
Selected
References
CRH CRH, ip Stress-induced increase in CRH as
common factor in multiple infan-
tile spasms etiologies
Limbic seizures, not spontaneous 61
65
69
70
71
Chronic
neonatal
stress
Limiting nest material Spontaneous spasms
Appropriate age
Cognitive deficits
Preliminary results (abstract only)
Effects of ACTH not tested
NMDA or
betametha-
sone/NMDA
NMDA ip at various postnatal
ages or betamethasone ip to
dam on G15, followed by
NMDA to
offspring on P15
Model of cryptogenic IS with flexion
spasms
Allows testing of possible
interventions
Cognitive changes
No chronic, spontaneous seizures
Treatments (ACTH, VGB) given prior
to spasms
72
73
74
75
76
77
TTX TTX ic infusion by osmotic pump
for 28 days, beginning on P10
Chronic blockade of neuronal activ-
ity leads to hyperexcitability and
seizures (spasms)
Video-EEG: hypsarrhythmia and
electrodecremental seizures
Spasms in clusters, especially during
slow wave sleep
Seizures occur at later developmental
stages
Treatment response unknown
Cognitive changes unknown
78
79
80
Multiple-hit Doxorubicin icv and
lipopolysaccharide ic on P3;
p-chlorophenylalanine ip on P5
Model of symptomatic IS with
severe, diffuse cortical injury
Appropriate age range
EEG changes
Cognitive changes
Need to have consistent pathologic
changes and distinguish toxin effects
from seizure effects
ACTH ineffective, VGB transiently
effective (both given after spasms
onset)
81
82
ARX conditional
knockout
Targeted deletion of ARX gene
from cortical GABAergic
interneurons
Mimics a known human mutation
that causes IS
Evolution of seizure type
EEG abnormalities
Cognitive changes unknown
Seizures occur at later developmental
stages
Treatment response unknown
83
84
ARX expansion Targeted expansion of polyala-
nine tract in ARX gene, causing
interneuronopathy
Mimics a known human mutation
that causes IS
Cognitive changes
EEG abnormalities
Treatment response unknown 85
Down
syndrome
GABAB receptor agonists ip to
Ts65Dn mice
Mimics Down syndrome, a human
chromosome disorder with high
incidence of IS
Spasms with polyspike wave bursts
and electrodecrement
ACTH, VGB reduced acute spasms
when given prior to GABAB-R
agonist
No chronic, spontaneous seizures
Requires exogenous agent (GABAB-R
agonist) to elicit spasms
86
Abbreviations: ACTH, adrenocorticotropic hormone; CRH, corticotropin releasing hormone; NMDA, N-methyl-D-aspartate; TTX, tetrodotoxin; ip,
intraperitoneal; G, gestational day; P, postnatal day; ic, intracerebral; icv, intracerebroventricular; ARX, Aristaless-related homeobox; IS, infantile spasms;
VGB, vigabatrin; GABAB-R, g-aminobutyric acid receptor type B.
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pretreatment prevented some extensor spasms seizures in
the Down syndrome model,86 reduced flexion seizures after
N-methyl-D-aspartate administration,72 and transiently sup-
pressed spasms in the multiple-hit model when given after sei-
zures began.81 Preliminary data suggest that carisbamate might
be beneficial in the multiple-hit model82 and that melanocortin
receptor type 4 agonists delay the onset to spasms induced by
N-methyl-D-aspartate.89 While not all models respond to
ACTH or other human treatments, a neuroprotective or rescue
effect of a treatment would certainly increase a model’s valid-
ity and point the way to testing some of the treatment protocols
discussed above. Eventually, one or more model could be
useful for comparing treatment efficacy prior to clinical trials.
Another way to approach the enigma of infantile spasms,
rather than to create a ‘‘model’’ of the disorder, is to investigate
whether a common final pathway can explain the pathophy-
siology across etiologies. If it is assumed that stress on the devel-
oping brain is a feature of many infantile spasms etiologies, then
the role of the synthesis, activation, and release of endogenous
stress hormones can be evaluated.70,90,91 A variety of stresses
in the immature brain cause the release of the neuropeptide
corticotropin-releasing hormone from cortical, hippocampal,
amygdala, and brainstem neurons.92 Corticotropin-releasing hor-
mone is highly convulsant at postnatal ages relevant to infantile
spasms but not at older ages.65,70 In the immature brain,
corticotropin-releasing hormone causes seizures, injures neurons,
causes atrophy of dendritic spines, and leads to long-term learning
and memory impairment.93,94 Preliminary data reports that
chronic stress in infant rats, induced by limiting the amount of
available nesting material in the cage,95 leads to spasm-like
events with electroencephalographic attenuation.71 Experimen-
tally, ACTH has been shown to suppress release or expression
of corticotropin-releasing hormone.61,96 The hypothesis that
stress-induced corticotropin-releasing hormone dysregulation
plays a role in the pathophysiology of infantile spasms can be
explored in conjunction with other infantile spasms models.
All of these infantile spasms models are at an early stage and
much more needs to be learned before clinical correlations can
be made. Conference attendees concluded that clinically rele-
vant insights from animal models are likely to emerge over
time.
Fundamental Remaining Questions and
Unresolved Issues
Infantile spasms is an epileptic encephalopathy of early infancy
with severe consequences in terms of future epilepsy and cog-
nitive impairment. The diagnosis is usually made by a pediatric
neurologist, pediatrician, or other health care practitioner who
treats young infants. The fundamental mechanisms and neuro-
biological basis of infantile spasms remain uncertain. It is
doubtful that a single mechanism can account for all of the
manifestations of infantile spasms; more likely, interacting
pathologies lead to one or more common pathways that cause
the disruption of neural circuit function in this syndrome.5,65
Whether the pathophysiology of infantile spasms explicitly
involves ACTH or melanocortins remains an important area
of investigation.
There are multiple critical remaining questions about
infantile spasms pathophysiology and treatment that will
inform clinicians about where the field is headed and stimu-
late further research. For example, why is the presentation
and treatment responsiveness of infantile spasms confined
to a specific developmental window? Can we make use of
this characteristic age dependence to develop a targeted treat-
ment related to etiology or identify a final common pathway
that is not critically reliant on etiology or age? What epilep-
togenic processes occur during the interval from neurologic
insult to development of spasms/hypsarrhythmia and how can
we intervene effectively during this latent period? Why does
ACTH work in some patients and etiologies and not in oth-
ers? Does ACTH cross the blood-brain barrier when adminis-
tered peripherally, and if not, how does it cause an effect on
the central nervous system? Do neurosteroids play a role?
Does ACTH exert its effects on melanocortin receptors inde-
pendent of the ACTH concentration? Given the associations
between cytokines and other mediators of inflammation and
cognitive effects, can developmental outcomes in infantile
spasms be improved with further understanding of the role
of inflammation? Do the anti-inflammatory effects of mela-
nocortins provide a sufficient rationale for infantile spasms
treatment?
This report should be viewed as a preliminary ‘‘status
report’’ of new and emerging concepts from clinical data on
infantile spasms and available animal models. Further scien-
tific progress will positively impact the comprehensive care
of children devastated by this severe epileptic
encephalopathy.
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